Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer
- Takeda Tatsuaki
- Yamamoto Hiromasa
- Kanzaki Hirotaka
- Suzawa Ken
- Yoshioka Takahiro
- Tomida Shuta
- Cui Xiaojiang
- Murali Ramachandran
- Namba Kei
- Sato Hiroki
- Torigoe Hidejiro
- Watanabe Mototsugu
- Shien Kazuhiko
- Soh Junichi
- Asano Hiroaki
- Tsukuda Kazunori
- Kitamura Yoshihisa
- Miyoshi Shinichiro
- Sendo Toshiaki
- Toyooka Shinichi
DOIAbstract
-amplified cell line BT-474. Lapatinib is also a molecular-targeted drug for HER2-positive breast cancer, which acquired the resistance to trastuzumab. Acquired resistance to lapatinib is also an issue to be conquered.We established trastuzumab/lapatinib-dual resistant cell line (named as BT-474-RL2) by additionally treating BT-474-R with lapatinib. We analyzed the mechanisms of resistance to trastuzumab and lapatinib. Besides, we analyzed the effect of the detected resistance mechanism in HER2-positive breast cancer patients. mRNA was correlated with worse prognosis in patients with HER2-positive breast cancer. plays an important role in acquired resistance to trastuzumab and lapatinib in HER2-positive breast cancer. Our data suggest that ...